Join Us for Lugano Elegance: Classic Cars, Charity, and Community/ We are excited to invite car enthusiasts and the general public to our classic car show in the scenic Piazzas of Lugano in May 18th.
plus
Actualités de Lugano -
Solid growth for Cornèr Group
Lugano (ots) - Faced with an uncertain geopolitical and economic situation, Cornèr Group's prudent policy and long-held pragmatic approach have once again proven to be winning qualities. Cornèr Group's 72nd financial year closed with revenues reaching CHF 506 million (+16 %) and a net profit of CHF 74.9 million (+41 %). This result allows the Group to further strengthen its capital solidity with its capital ...
2 DocumentsplusGood Results for the Cornèr Group
Lugano (ots) - Following a highly turbulent year, which saw the outbreak of the war in Ukraine and abrupt interest rate rises by the main central banks around the world, the Cornèr Group has now posted good results in its 71st Annual Report. Revenues increased to CHF 436 million, whilst the net profit rose to CHF 53.2 million, representing a strong increase compared to the previous year (CHF 22.7 million). ...
2 DocumentsplusCornèr Group launches Visa Commercial Pay as first banking group in Europe
Lugano/Zurich (ots) - Starting from Switzerland, Cornèr Group introduces Visa Commercial Pay (VCP), supporting companies to quickly digitize B2B payments. The increasing pace of digitalisation in business processes creates new demands for payment capabilities of companies. A comprehensivesolution by ...
Un documentplusENG - Temera, Luxochain & Polygon, announce the collaboration with Bulgari for the launch of the new Octo Finissimo Ultra
Lugano, Switzerland (ots/PRNewswire) - Temera, Luxochain and Polygon are pleased to announce their role as partners for the launch project of the new model Octo Finissimo Ultra, available in a limited edition of only 10 pieces. Bulgari with this initiative masters again its leadership as innovator in the hard luxury ...
plusLugano NFT Week: Lugano is becoming a Blockchain & Crypto-Friendly City
Lugano, Switzerland (ots/PRNewswire) - From 15-21 November Lugano Living Lab, the digital innovation laboratory of the City of Lugano, has promoted an unprecedented exhibition that explores the fascinating world of NFT and Crypto Art with an exhibition, events and dedicated workshops. Lugano is increasingly a Blockchain & Crypto-Friendly City. After the launch at the ...
plusLugano NFT Week: Lugano is becoming a Blockchain & Crypto-Friendly City
Lugano, Switzerland (ots/PRNewswire) - From 15-21 November Lugano Living Lab, the digital innovation laboratory of the City of Lugano, has promoted an unprecedented exhibition that explores the fascinating world of NFT and Crypto Art with an exhibition, events and dedicated workshops. Lugano is increasingly a Blockchain & Crypto-Friendly City. After the launch at the ...
plusLugano NFT Week: Lugano is becoming a Blockchain & Crypto-Friendly City.
Lugano, Switzerland (ots/PRNewswire) - From 15-21 November Lugano Living Lab, the digital innovation laboratory of the City of Lugano, promotes an unprecedented exhibition that explores the fascinating world of NFT and Crypto Art with an exhibition, events and dedicated workshops. An unmissable opportunity to look into this new sector of digital art, discover ...
plusEuropean Society for Medical Oncology (ESMO)
Launch of ESMO Virtual Plenaries Brings Rapid Access to Ground-Breaking Cancer Research
plusEuropean Society for Medical Oncology (ESMO)
2ESMO supports women in South Africa to become autonomous workers
plusEuropean Society for Medical Oncology (ESMO)
Breast cancer patients use Twitter as a non-medical forum to share their experiences
Lugano/Munich (ots) - Twitter is a place where many cancer patients share and discuss their experiences, a study at the ESMO 2018 Congress reveals, based on analysis of the contents of over 6,000 tweets and retweets about breast cancer. The study was part of a larger, multidisciplinary project to observe the presence of different diseases on social media. The data ...
plusEuropean Society for Medical Oncology (ESMO)
ESMO Publishes New Position Paper on Supportive and Palliative Care
Lugano (ots) - ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care, calling attention to the evolving and growing gap between the needs of cancer patients and the actual provision of patient-centred care. "New studies show that there may be a gap between what doctors think is important for patients, and what patients really need. With this position ...
plusEuropean Society for Medical Oncology (ESMO)
CAREFOR calls on EU to safeguard independent academic research
plusHelsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
Lugano, Switzerland and San Diego (ots/PRNewswire) - Phase 2 study results presented at American Society of Hematology Annual Meeting on Saturday, December 3, 2016 Global Phase 3 study site recruitment is ongoing Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, ...
plusHelsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting
Lugano, Switzerland and San Diego (ots/PRNewswire) - Data to be presented on December 3, 2016; Abstract now available online Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel ...
plusHelsinn Group Introduces Helsinn Investment Fund
Lugano, Switzerland (ots/PRNewswire) - ~ Helsinn Group creates new investment fund in 40th anniversary year ~ ~ The new fund will focus on supporting early-stage investment opportunities in areas of high unmet patient need ~ Helsinn, the Swiss Pharmaceutical Group focused on building quality cancer care, today introduces Helsinn Investment Fund S.A. ("the Fund"), a fund focused on early-stage investment opportunities in ...
plusHelsinn Celebrates its 40th Anniversary
Lugano, Switzerland (ots/PRNewswire) - ~ 40 years helping patients achieve a better quality of life ~ Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, is delighted to launch its 40th anniversary celebrations in San Francisco, US, at the time of the JP Morgan 34th Annual Healthcare Conference. Helsinn believes its core values of respect, integrity and quality have underpinned four decades of ...
plusEuropean Society for Medical Oncology (ESMO)
ESMO announces annual medical oncology congress platform in Europe from 2016
Lugano, Switzerland (ots) - The European Society for Medical Oncology, the pan-European association representing medical oncologists in Europe and beyond, has announced that it will be organising an annual Congress in Europe from 2016. A record 19,809 participants from 134 countries gathered at ESMO 2014 in Madrid to hear the results of trials which included ...
plusEisai Oncology & Helsinn Group to Present New CINV Research at 2014 International Symposium on Supportive Care in Cancer
Woodcliff Lake, NJ, and Lugano, Switzerland (ots) - Eisai Inc. and Helsinn Group announced today that several abstracts highlighting data analyses of NEPA, an investigational oral fixed- dose combination of netupitant and palonosetron being evaluated for the prevention of chemotherapy-induced nausea and vomiting ...
plusHelsinn Therapeutics (U.S.), Inc. Strengthens its Board of Directors
Lugano, Switzerland (ots) - Helsinn Group, the Company focused on building quality cancer care, announced today the appointment of Dr. Philip S. Schein, to the Board of Directors of its U.S. subsidiary, Helsinn Therapeutics Inc. ("HTU"), effective 8 May 2014. Dr. Philip Schein was the former Founder, Chairman and CEO of US Biosciences, Inc., and Chair of the Clinical Investigations Committee of the National Cancer ...
plusHelsinn promotes the use of mobile technology in cancer supportive care through mobile health
Lugano, Switzerland (ots) - The pharmaceutical group in Ticino, global leader in cancer supportive care, supports the International Conference on mobile technology dedicated to improve the quality of life of people with cancer in collaboration with SDA Bocconi and CERGAS Bocconi. The combination of medicine and mobile technology to improve the quality of life of people ...
plusHelsinn announces European Medicines Agency acceptance of regulatory submission for netupitant-palonosetron fixed dose combination (NEPA)
Lugano, Switzerland (ots) - NEPA is currently under development for the treatment of chemotherapy-induced nausea and vomiting The Swiss pharmaceutical Helsinn Group announced today that on January 22nd the European Medicines Agency (EMA) determined netupitant-palonosetron fixed dose combination (NEPA) Marketing ...
plusHelsinn Group and Angelini ink an agreement for license rights to phase-III ghrelin receptor agonist Anamorelin in Central & Eastern Europe
Lugano, Schweiz (ots) - Swiss Pharma Group Helsinn grants exclusive distribution and licensing rights to Angelini, through its subsidiary company CSC Pharmaceuticals, for the commercialization in Austria, Bulgaria, Czech Republic, Hungary , Poland, Romania, Slovak Republic, Georgia, Russia and the other CIS ...
plusSwiss-based Helsinn Group and Mundipharma sign for rights to Phase III Netupitant-Palonosetron fixed dose combination for China
Lugano, Switzerland (ots) - The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution ...
plusSwiss-based Helsinn Group and Mundipharma sign for rights to Phase III Netupitant-Palonosetron fixed dose combination for China
Lugano, Switzerland (ots) - The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution ...
plusHelsinn and Italfarmaco reinforce their alliance through the grant of rights to phase-III ghrelin receptor agonist Anamorelin in Italy
Lugano, Switzerland (ots) - Helsinn Group grants exclusive distribution and licensing rights to Italfarmaco for the commercialization of its compound currently in development for the treatment of anorexia-cachexia syndrome related to non-small cell lung cancer (NSCLC) Helsinn Group is pleased to announce that ...
plusEuropean Society for Medical Oncology (ESMO)
Defending Medical Oncology to Assure Quality Care for Cancer Patients / ESMO releases position paper on medical oncologist's role
Lugano (ots) - Medical oncologists have a vital role to play in cancer care, particularly as treatments become ever more complex, a new position statement from the European Society for Medical Oncology says (http://www.presseportal.ch/go2/new_position_statement ). Medical oncologists are specialist cancer physicians ...
plusHelsinn Group and Eisai announce FDA acceptance of New Drug Application for investigational compound netupitant 300 mg + palonosetron 0.50 mg (NEPA)
Lugano, Switzerland/Woodcliff Lake, NJ, USA (ots) - Seeking indication for prevention of chemotherapy-induced nausea and vomiting Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the submission of the New Drug Application (NDA) for the investigational ...
plusHelsinn Group's representative office in China: Official inauguration
Lugano, Switzerland - Beijing, PRC (ots) - Helsinn Group, the independent, privately-owned, Swiss pharmaceutical company, with a worldwide presence built over 35 years, lands in China. Helsinn's Representative Office was officially inaugurated in Beijing, PRC yesterday. With headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United ...
plusEuropean Society for Medical Oncology (ESMO)
Untreated cancer pain a 'scandal of global proportions,' ESMO-led survey shows / New global study reveals a pandemic of intolerable pain affecting billions, caused by pain medicines overregulation
Lugano (ots) - A ground-breaking international survey published today, shows that more than half of the world's population live in countries where regulations aiming to stem drug misuse leave patients without access to opioid medicines for managing cancer pain. The results from the Global Opioid Policy Initiative ...
plus
12Suivant